Loading...
Market
Outcome of Pfizer's next DMD gene therapy trial by end of 2025?
5
Resolution / Starting Odds
Success • 33%
Partial Success • 33%
Failure • 33%
Clinical trial results or Pfizer announcements
Story
Pfizer's ($PFE) Gene Therapy for Duchenne Muscular Dystrophy Fails Phase 3 Trial on Wednesday
Jun 12, 2024, 08:37 PM
Pfizer ($PFE) has announced on Wednesday that its Phase 3 study of an investigational gene therapy for ambulatory boys with Duchenne Muscular Dystrophy did not meet its primary endpoint. The study, which focused on boys aged 4-7, showed no significant improvement in motor function compared to a placebo. Additionally, key secondary endpoints also did not show significant differences. This marks the second failure of a gene therapy for Duchenne Muscular Dystrophy in recent trials, raising concerns about the efficacy of such treatments.
View original story
Similar markets
Yes • 50%
No • 50%
Continue development • 33%
Discontinue program • 33%
Partner with another company • 33%
Successful phase 3 trial by another company • 25%
New regulatory approval • 25%
Major partnership or acquisition • 25%
Another failed trial • 25%
Yes • 50%
No • 50%
10-20 • 33%
21-30 • 33%
31+ • 34%
Positive results • 33%
Neutral results • 34%
Negative results • 33%
DFNB1 • 50%
DFNB4 • 25%
DFNB7/11 • 25%